Ozempic vs. Wegovy vs. Zepbound: What the 2026 Data Actually Shows for Women Over 40

By Dr. Shweta Patel, Board-Certified OB/GYN | Gaya Wellness

Published March 18, 2026 • 10-minute read

People ask me this constantly: “Ozempic, Wegovy, Zepbound — which one should I take?”

I get it. You’re on Instagram, and one woman lost 40 pounds on Zepbound. Your coworker swears by Wegovy. Your neighbor’s doctor prescribed Ozempic off-label, and she’s down two sizes. Meanwhile, you’re sitting in your late 40s, watching the scale creep up despite doing everything “right,” and trying to figure out which of these medications is the magic one.

Here’s what I tell every woman who asks me this in my practice: the comparison everyone’s Googling is real, but it’s incomplete. There is head-to-head data now. One medication does produce more weight loss than the other. I’ll give you the numbers. But if you’re a woman over 40 — especially if you’re in perimenopause or menopause — the variable that determines your results isn’t which GLP-1 you choose. It’s whether anyone has addressed your hormones first.

Let me walk you through what the 2026 data actually shows.

The Quick Translation: What Each Drug Actually Is

Before we get to the data, let’s cut through the pharma branding, because the naming is designed to confuse you.

There are two molecules. That’s it. Two drugs, four brand names:

• Semaglutide is the active ingredient in both Ozempic and Wegovy. It’s a GLP-1 receptor agonist — it mimics one gut hormone that suppresses appetite, slows gastric emptying, and improves insulin sensitivity. Ozempic is FDA-approved for type 2 diabetes. Wegovy is FDA-approved for weight management. Same drug, different dose, different indication.
• Tirzepatide is the active ingredient in Mounjaro and Zepbound. It’s a dual GIP/GLP-1 receptor agonist — it mimics two gut hormones instead of one. Mounjaro is FDA-approved for diabetes. Zepbound is FDA-approved for weight management.

And as of January 2026, there’s a new option: oral Wegovy — a daily semaglutide pill (25mg) that the FDA approved in December 2025. It’s now broadly available in U.S. pharmacies. The OASIS 4 trial showed approximately 16.6% weight loss at 64 weeks with full adherence — comparable to the injectable. Self-pay starts at $149/month for the starting dose.

So when someone asks “Ozempic vs. Wegovy vs. Zepbound,” the actual clinical question is: semaglutide vs. tirzepatide. One hormone pathway or two. And now: injection or pill.

The Head-to-Head Data: Tirzepatide vs. Semaglutide

For years, we compared these drugs by looking at separate clinical trials with different patient populations. That changed with SURMOUNT-5 — the first direct head-to-head comparison.

Published in The New England Journal of Medicine in July 2025, SURMOUNT-5 randomized 751 adults with obesity (no diabetes) to receive maximum tolerated doses of either tirzepatide (10 or 15mg) or semaglutide (1.7 or 2.4mg) for 72 weeks. The results:

• Average weight loss: 20.2% with tirzepatide vs. 13.7% with semaglutide. That’s a 6.5 percentage point difference — about 47% more relative weight loss.
• Absolute weight lost: 22.8 kg (50.3 lbs) with tirzepatide vs. 15.0 kg (33.1 lbs) with semaglutide.
• Waist circumference: 18.4 cm reduction with tirzepatide vs. 13.0 cm with semaglutide.
• Achieving ≥15% weight loss: 64.6% on tirzepatide vs. 40.1% on semaglutide.
• Achieving ≥25% weight loss: 31.6% on tirzepatide vs. 16.1% on semaglutide.

The safety profiles were similar between both drugs, with GI side effects being most common during dose escalation. Interestingly, GI events causing discontinuation were actually higher with semaglutide (5.6%) than tirzepatide (2.7%). (Source: American College of Cardiology)

So yes: tirzepatide produces more weight loss than semaglutide. That is now established by a Phase 3b head-to-head trial in the world’s most respected medical journal. It’s not close.

But here’s what I need you to understand: these numbers are population averages in a trial that didn’t stratify by menopausal status. And that matters. A lot.

The Variable Nobody’s Comparing: Your Hormones

Here’s what no Ozempic vs. Zepbound comparison article on the internet is telling you: for women in perimenopause and menopause, the hormonal environment underneath the medication may determine your results more than which GLP-1 you choose.

In January 2026, Mayo Clinic published a study in The Lancet Obstetrics, Gynaecology, & Women’s Health that changes this entire conversation. Postmenopausal women who combined hormone replacement therapy (HRT) with tirzepatide lost 35% more weight than women on tirzepatide alone. (Source: Mayo Clinic News Network)

Read that again. The difference between tirzepatide with HRT and tirzepatide without HRT (35% more weight loss) is actually larger than the difference between tirzepatide and semaglutide in SURMOUNT-5 (about 47% relative difference, but from a different baseline). The hormonal variable is on the same order of magnitude as the drug variable.

This makes biological sense. Declining estrogen during menopause causes insulin resistance, visceral fat accumulation, muscle loss, and metabolic slowdown. A GLP-1 suppresses your appetite and improves insulin signaling — but it can’t fix an endocrine system that’s running on empty. It’s like upgrading the engine without fixing the fuel system.

A 2024 study in the journal Menopause showed the same pattern with semaglutide: women combining semaglutide with HRT lost 16% of body weight at 12 months compared to 12% without hormones — roughly 30% greater relative weight loss. (Source: PubMed)

So here’s the uncomfortable truth I tell my patients: you can spend months debating Ozempic vs. Zepbound, but if nobody has checked your estradiol, progesterone, and testosterone levels, you’re optimizing the wrong variable.

The Bone and Muscle Crisis in the Fine Print

This is the part of the GLP-1 comparison that nobody wants to discuss — and it matters more for women over 40 than for any other population.

Research presented at the 2026 AAOS Annual Meeting found that GLP-1 users have approximately a 30% higher risk of developing osteoporosis compared to non-users. Studies have shown that up to 40% of weight lost on GLP-1 medications comes from lean body mass — not fat. That means muscle. That means bone.

Now layer that on top of menopause, which already accelerates bone loss and muscle wasting due to declining estrogen. You have a compounding crisis: the medication is stripping muscle and bone from a body that’s already losing both.

This applies equally to semaglutide and tirzepatide. The SURMOUNT-5 trial authors themselves noted that weight loss may coincide with loss of bone mineral density and called for BMD monitoring. And the AAOS data didn’t distinguish between GLP-1 types.

This is why “which injection should I pick?” is the wrong first question. The right first questions are: Has anyone checked my bone density? Is my hormonal environment protecting my bones and muscle? Am I getting enough protein? Am I doing resistance training? Is a physician monitoring my body composition — not just my weight?

A woman in menopause on any GLP-1 needs her bone density tracked via DEXA scan, protein optimized to 0.7–1.0g per pound of lean mass, a resistance training protocol, and her hormones evaluated — because HRT itself preserves both muscle mass and bone density.

Access, Cost, and the 2026 Reality

The best GLP-1 in the world doesn’t work if you can’t get it, can’t afford it, or can’t stay on it. Here’s where things stand in March 2026:

Ozempic (semaglutide injection, for diabetes)

Still the most commonly prescribed GLP-1, largely because insurance covers it for type 2 diabetes. Off-label use for weight loss is common but not FDA-approved under this brand. Self-pay pricing dropped to $349/month (down from $499) for existing patients. Not the optimal choice for pure weight management — the dosing wasn’t designed for it.

Wegovy (semaglutide injection + oral pill, for weight loss)

FDA-approved for weight management. The injectable is dosed higher (up to 2.4mg) than Ozempic for greater weight loss. The new oral pill (25mg daily, launched January 2026) offers similar efficacy to the injectable at lower cost — self-pay starts at $149/month for the starting dose. Insurance coverage varies widely; many plans still exclude weight loss medications.

Zepbound (tirzepatide injection, for weight loss)

FDA-approved for weight management. Produces the most weight loss of any currently available GLP-1 based on SURMOUNT-5 data. Insurance coverage is limited and varies by plan. Out-of-pocket cost is approximately $1,000/month for brand-name.

Compounded options

Compounded semaglutide and tirzepatide remain available through 503B outsourcing pharmacies that compound under FDA oversight. At Gaya Wellness, we prescribe compounded formulations through regulated pharmacies — which means consistent access, physician-managed dosing, and pricing that’s typically a fraction of brand-name cost.

The access landscape is the real reason “which one is best?” doesn’t have a universal answer. The medication you can afford, access consistently, tolerate, and stay on with physician oversight will outperform the “better” medication you can’t get or can’t sustain.

Why the Medication Matters Less Than the Protocol Around It

Here’s what I see in my practice every week: a woman comes in already on a GLP-1 she got from a telehealth company. Maybe she’s lost some weight. Maybe she hasn’t. But nobody ordered labs before they prescribed. Nobody checked her hormones. Nobody is monitoring her bone density or body composition. Nobody adjusted her dose based on her actual metabolic response. And nobody has an exit strategy for when she wants to stop the medication.

This is the prescription mill model: get the drug into your hands as fast as possible, charge monthly, never look back. And it’s why the “Ozempic vs. Zepbound” debate misses the point. The protocol around the medication — not the medication itself — is what separates a good outcome from a mediocre one.

At Gaya Wellness, I built the Weight Loss Concierge program for exactly this reason. Here’s how we approach the GLP-1 decision for women over 40:

• We start with your biology. Every member gets a comprehensive 50+ biomarker panel — metabolic markers, full hormonal panel, thyroid, insulin, cortisol. You cannot choose the right medication without this data. And most telehealth companies never order it.
• We factor in your hormonal status. If you’re in perimenopause or menopause, we evaluate whether HRT should come first or alongside your GLP-1. The Mayo Clinic data says this decision is worth 35% more weight loss.
• We customize the medication to your reality. Not every woman needs the same drug, dose, or approach. That’s why we built three tiers:

• Foundation (GLP-1 Access) — $149/mo: Full physician-led support with prior authorization assistance for insurance-covered brand-name medications like Wegovy or Zepbound. You bring the medication; we bring the strategy, labs, and oversight.
• Premium (GLP-1 Included) — $349/mo: Everything in Foundation plus compounded semaglutide or tirzepatide shipped to your door. Physician-managed dosing. Custom meal plans tailored to your metabolic profile.
• Concierge (GLP-1 + HRT) — $549/mo: The complete protocol. GLP-1 medication combined with bioidentical hormone replacement therapy. This is the tier the research points to — and it’s the one that produces the best outcomes for women in menopause.

Weekly check-ins. Dose adjustments based on your actual response. Body composition tracking. Resistance training guidance. And a board-certified OB/GYN who understands that for women over 40, weight loss is a hormonal problem with a metabolic solution — not a prescription and a prayer.

The Correct Order of Operations for Women Over 40

If there’s one thing I want you to take from this article, it’s this: the order matters more than the brand.

Step 1: Assess the full picture.
Comprehensive labs. Full hormonal panel. Metabolic markers. Insulin, thyroid, cortisol — the whole landscape. You cannot make a smart medication decision without data.

Step 2: Optimize hormones if indicated.
If you’re in perimenopause or menopause and your estradiol, progesterone, or testosterone are depleted, HRT creates the metabolic environment where any GLP-1 works better. This isn’t optional. It’s the foundation.

Step 3: Choose the right GLP-1 based on your clinical reality.
Tirzepatide produces more weight loss on average. Semaglutide has more delivery options (including the new oral pill) and broader insurance coverage. The “best” one is the one that fits your body, your budget, your tolerance profile, and your physician’s clinical judgment.

Step 4: Protect your bones, muscle, and metabolic future.
Protein optimization. Resistance training. DEXA scans. Ongoing lab monitoring. A plan for what happens when — not if — you taper off the medication. Without this, you’re trading short-term weight loss for long-term fragility.

That’s the protocol. That’s what the research supports. And that’s what virtually nobody comparing Ozempic vs. Wegovy vs. Zepbound online is telling you.

Stop Comparing Medications. Start Comparing Protocols.

If you’ve been going back and forth between Ozempic, Wegovy, and Zepbound — reading comparison articles, watching TikTok transformations, trying to decode insurance formularies — I want to redirect your energy.

The medication is a tool. An important tool. But for women over 40, it’s the fourth or fifth most important variable in whether you actually lose weight and keep it off. Your hormonal status. Your physician’s clinical expertise. Your lab work. Your bone and muscle protection plan. These come first. The brand name on the injection pen comes after.

The Weight Loss Concierge program at Gaya Wellness was built for women who want a physician-led protocol — not a prescription and a hope. Board-certified OB/GYN from day one. Labs before medication. Hormonal optimization layered with GLP-1 therapy. And a plan that’s designed for your biology, not for a pharma company’s bottom line.

Your body changed. Your approach needs to change with it.